Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03920267 · ClinicalTrials.gov registry record · Phase 2
Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 261
- Enrollment target
NCT03920267 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 261 participants.
The verdict
NCT03920267, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 261 participants
- Enrollment target
Study Summary
The main objective of the trial is to characterize the long-term safety and tolerability of BMS-986165 in subjects with Systemic Lupus Erythematosus (SLE).
Interventions
- DRUG BMS-986165
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2019-03-26 |
| Est. Completion | 2025-03-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03920267
The ClinicalTrials.gov registry entry for NCT03920267 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 261 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-986165 is the first listed.
NCT03920267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03920267 about?
NCT03920267 is a clinical study titled "Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus". The main objective of the trial is to characterize the long-term safety and tolerability of BMS-986165 in subjects with Systemic Lupus Erythematosus (SLE).
What is the current status of trial NCT03920267?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 261 participants. The study started on 2019-03-26. Estimated completion is 2025-03-21.
What interventions are being tested in trial NCT03920267?
The interventions under investigation include: BMS-986165 (DRUG).
Who is sponsoring clinical trial NCT03920267?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.